Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high risk acute myeloid leukemia or myelodysplastic syndrome

Myeloid Leukemia ◽

Low Dose ◽

Allogeneic Transplantation ◽

Donor Lymphocyte Infusion ◽

Disease Relapse ◽

Faculty Opinions recommendation of A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1119427.575617 ◽

2008 ◽

Author(s):

Arati Rao

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Low Dose ◽

Randomized Study ◽

Front Line ◽

Line Therapy ◽

Low Dose Cytarabine ◽

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Leukemia ◽

10.1038/s41375-018-0312-9 ◽

2018 ◽

Vol 33 (2) ◽

pp. 379-389 ◽

Cited By ~ 145

Author(s):

Jorge E. Cortes ◽

Florian H. Heidel ◽

Andrzej Hellmann ◽

Walter Fiedler ◽

B. Douglas Smith ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Low Dose ◽

Newly Diagnosed ◽

Low Dose Cytarabine ◽

132 RETROSPECTIVE ANALYSIS OF HIGH-RISK MYELODYSPLASTIC SYNDROME AND SECONDARY ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH ALLOGENEIC TRANSPLANTATION AT SAN RAFFAELE SCIENTIFIC INSTITUTE: A SINGLE CENTER EXPERIENCE

Leukemia Research ◽

10.1016/s0145-2126(15)30133-8 ◽

2015 ◽

Vol 39 ◽

pp. S67-S68 ◽

Cited By ~ 1

Author(s):

F. Pavesi ◽

C. Messina ◽

M. Carrabba ◽

S. Claudiani ◽

E. Sala ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Retrospective Analysis ◽

Myeloid Leukemia ◽

Allogeneic Transplantation ◽

Single Center ◽

Single Center Experience ◽

Secondary Acute Myeloid Leukemia ◽

Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with de novo acute myeloid leukemia and high-risk myelodysplastic syndrome aged over 70 years

Hematology ◽

10.1080/16078454.2021.2009642 ◽

2021 ◽

Vol 26 (1) ◽

pp. 1040-1045

Author(s):

Fang Wang ◽

Wenyan Xu ◽

Li Liu ◽

Xiuhong Ren ◽

Pingping Liu ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Low Dose ◽

De Novo ◽

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years

Hematology/Oncology and Stem Cell Therapy ◽

10.1016/j.hemonc.2019.01.002 ◽

2019 ◽

Vol 12 (2) ◽

pp. 105-109 ◽

Cited By ~ 1

Author(s):

Curtis Lachowiez ◽

Rachel J. Cook ◽

Brandon Hayes-Lattin ◽

Richard T. Maziarz ◽

Uma Borate ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Allogeneic Transplantation ◽

Transplantation Outcomes ◽

Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Haematologica ◽

10.3324/haematol.2016.153130 ◽

2016 ◽

Vol 102 (2) ◽

pp. e47-e51 ◽

Cited By ~ 5

Author(s):

Dominik Selleslag ◽

Stefan Suciu ◽

Giovanna Meloni ◽

Petra Muus ◽

Constantijn J.M. Halkes ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Phase I ◽

Myeloid Leukemia ◽

Low Dose ◽

Remission Induction ◽

Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS)

Bone Marrow Transplantation ◽

10.1038/s41409-021-01464-x ◽

2021 ◽

Author(s):

Xavier Poiré ◽

Carlos Graux ◽

Aurélie Ory ◽

Julie Herman ◽

Frédéric Baron ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Stem Cell ◽

Stem Cell Transplantation ◽

Myeloid Leukemia ◽

Low Dose ◽

Donor Lymphocyte Infusion ◽

Sequential Administration ◽

A Prospective Study ◽

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186

Leukemia & Lymphoma ◽

10.3109/10428194.2012.737917 ◽

2012 ◽

Vol 54 (4) ◽

pp. 760-766 ◽

Cited By ~ 30

Author(s):

David A. Macdonald ◽

Sarit E. Assouline ◽

Joseph Brandwein ◽

Suzanne Kamel-Reid ◽

Elizabeth A. Eisenhauer ◽

...

Keyword(s):

Clinical Trials ◽

Acute Myeloid Leukemia ◽

High Risk ◽

Elderly Patients ◽

Myeloid Leukemia ◽

Low Dose ◽

Group Trial ◽

Low Dose Cytarabine ◽

Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic syndrome

Cancer Science ◽

10.1111/cas.15048 ◽

2021 ◽

Author(s):

Yunxiong Wei ◽

Xia Xiong ◽

Xin Li ◽

Wenyi Lu ◽

Xiaoyuan He ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Maintenance Therapy ◽

Myeloid Leukemia ◽

Low Dose ◽

Post Transplant ◽

Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome

Annals of Hematology ◽

10.1007/s00277-020-04291-0 ◽

2020 ◽

Author(s):

Márcio Tavares ◽

Sérgio Chacim ◽

José Mário Mariz

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Myeloid Leukemia ◽

Low Dose ◽

Compassionate Use ◽

Refractory Acute Myeloid Leukemia ◽

Low Dose Cytarabine ◽